Pathway

Calm under stress

Physiological arousal recovery

The Alarm That Will Not Stand Down

32 blends on this site modulate it.

Also searched as Anxiety · Physiological arousal recovery.

Calm is not the absence of a threat; it is a nervous system that can stop responding to one. Trace it upward: inhibitory GABA tone, cortisol rhythm, and the gut that helps set both.

In depth

Persistent apprehension and physical arousal that outlasts the situation that caused it.

What drives it

Calm reduces it.

GABA is the principal inhibitory neurotransmitter of the CNS and the direct target of anxiolytic pharmacotherapy; deficient GABAergic tone is central to the aetiology and treatment of anxiety disorders. PMC10845093

Lowers cortisol increases it.

Endocrine dysfunction of the hypothalamic-pituitary-adrenal axis is a core mechanism in anxiety: HPA activation drives glucocorticoid secretion and the negative-feedback loop that normally restrains it is impaired in anxiety disorders (review, DOI 10.3389/fnins.2024.1501134). Convergent: HPA axis dysfunction is associated with MDD, PTSD and anxiety, and cortisol is named one of the most significant biomarkers of anxiety disorders. 'biomarker of' is an association claim, not a demonstration of causation — the reviews do not establish that cortisol elevation causes the anxiety phenotype. doi 10.3389/fnins.2024.1501134

Gut barrier reduces it.

Two-sample bidirectional Mendelian randomization over 119 bacterial genera found specific gut genera causally related to anxiety disorders, with multivariable analysis pointing to a metabolite-dependent mechanism driven partly by cortisol (PMC11035889). Note: Mendelian randomization is causal inference from genetic instruments, not a randomized trial. PMC11035889

Mood (serotonin) reduces it.

Serotonin reuptake inhibitors ARE an evidence-based first-line pharmacological treatment for anxiety disorders and current practice guidelines recommend SSRIs or SNRIs as preferred first-line therapy. Genetic variation in the serotonin transporter gene SLC6A4 is linked to increased anxiety risk, and 5-HTT, 5-HT1A and 5-HT2 receptors are the studied targets. A weak case in depression does not transfer to anxiety, and the reverse is equally true. The same literature states the these medications fail to improve anxiety symptoms in a significant proportion of patients, and the relation between the genetic background of these targets and anxiety symptoms is largely unknown. doi 10.3389/fpsyt.2020.548505 · PMC3677985

Alertness chemical increases it.

NBK441870 — Noradrenaline is the fight-or-flight transmitter and is implicated across anxiety disorders; SNRIs sit alongside SSRIs in first-line guidance. A provocation test shows the receptor is altered, not just the level: clonidine, an alpha-2 agonist, normally stimulates growth-hormone release, and the growth-hormone response to clonidine is blunted in GAD patients. The source states its own ambiguity: it is not yet known whether this reflects alpha-2 receptor down-regulation from chronic central noradrenergic overactivity, or a different abnormality as in depression. The finding is solid; its interpretation is not settled.

Quiets overexcitation increases it.

Glutamate is the excitatory counterweight to GABA inhibition, and a full review is devoted to glutamate systems in dsm-5 anxiety disorders. Anatomically the case is explicit: the basolateral amygdala activates the central amygdala directly through an excitatory glutamatergic pathway, as well as through a relay of inhibitory GABAergic interneurons — the two transmitters are wired into the same circuit in opposition. Why it matters clinically: serotonin and GABA drugs fail a significant proportion of patients, which is precisely why glutamate-modulating agents are being pursued as alternatives — the unmet need defines the gap. PMC7710541

Endocannabinoid tone reduces it.

GABA is not the only brake, and the review says so directly: many other neurotransmitters modulate anxiety responses in the amygdala, including serotonin, opioid peptides, endocannabinoids, neuropeptide Y, oxytocin and corticotropin-releasing hormone. Scope, stated plainly: the source that names endocannabinoids here explicitly declines to EXAMINE them in detail — it is an enumeration, not a demonstration. This edge is entered on the strength of that enumeration and needs its own review. The mechanism is now well evidenced in humans, and the definitive clinical trial failed. Both ARE recorded. Human randomized, double-blind, placebo-controlled: the FAAH inhibitor PF-04457845 (orally daily, 10 days; n=16 active vs 29 placebo) produced a ten-fold increase in baseline anandamide, and this was associated with potentiated recall of fear-extinction memory at 24 hours, attenuated autonomic stress reactivity measured by electrodermal activity, and protection against stress-induced negative affect measured by facial electromyography (Biol Psychiatry 2020;87:538, PMID 31590924). Human genetics agrees: people homozygous for a loss-of-function FAAH mutation show the same phenotype — the drug reproduces a natural genotype. Imaging shows the enzyme tracks the fear response: in 28 healthy people scanned with PET using the FAAH radiotracer [11C]curb, amygdala FAAH binding correlated positively with BOLD signal during processing of angry and fearful faces — more of the enzyme that destroys anandamide, more amygdala reactivity (PMC10206405). Mechanism: FAAH inhibition raises anandamide in the basolateral amygdala, increasing CB1 receptor signaling, which attenuates GABAergic transmission by long-term depression of inhibitory transmission — lifting a brake on the BLA neurons recruited to encode extinction. And here is the part that must travel with all of it: in a randomized clinical trial of 100 patients, A FAAH inhibitor did NO better than placebo at enhancing the response to exposure-based therapy in PTSD (PMC12923879). The biomarker moved ten-fold, the imaging correlated, the genetics agreed, the experimental-medicine endpoints improved — and the clinical endpoint did not. A further randomized placebo-controlled trial combining FAAH inhibition with internet-delivered CBT was run in 2025 (doi 10.1038/s41386-025-02128-w). This is the exact shape of error a mechanism-forward atlas is prone to: a beautiful pathway with a null trial at the end of it. The edge stands as mechanism; it does not support a clinical claim. doi 10.1038/s41386-025-02128-w · PMID 31590924 · PMC10206405

Stress-relapse axis increases it.

10.1371/journal.pone.0008528 — Stress reaches anxiety through the HPA axis, but CRF also acts in the amygdala in its own right: corticotropin-releasing factor coordinates the endocrine, autonomic, behavioral and immune responses to stress and also acts as a neurotransmitter OR neuromodulator in the amygdala, dorsal raphe, hippocampus and locus coeruleus. Abnormal signaling at CRF1 and CRF2 receptors is proposed to contribute to anxiety and depression. This is a second, parallel route alongside the CRF → ACTH → HPA Axis / Cortisol link — the peptide reaches behavior without going through cortisol at all, which is why the two arms can dissociate. doi 10.1371/journal.pone.0008528

Feeding drive reduces it.

10.1038/npp.1993.35 — But microinjection into the central nucleus of the amygdala did not increase food intake while still acting on anxiety — the anxiolytic action is anatomically separable from the feeding action, mediated by Y1 receptors in the amygdala rather than the hypothalamic mechanism that drives intake (Neuropsychopharmacology, npp199335). Human genetics: a single-nucleotide polymorphism in the NPY promoter, rs16147, decreases NPY expression and correlates with enhanced anxiety traits — less peptide, more anxiety, in people. Human biomarker: adults with PTSD have lower NPY in cerebrospinal fluid. Human intervention, stated cautiously: a clinical trial concluded that intranasal NPY may be associated with anxiolytic effects in adults with PTSD (Sayed 2018), with a follow-up trial ongoing — the hedge is the authors' own and is kept. the anatomical and receptor work is rodent; the genetics and CSF findings are human. doi 10.1038/npp.1993.35

Brain inflammation increases it.

Observationally the association is large and dose-dependent: in up to 144,890 UK Biobank participants, CRP concentration was associated with depressive and anxiety symptom scores and with probable diagnoses of depression and generalized anxiety disorder in a dose-response fashion — stronger for depression than anxiety, and stronger in women. In joint UKB+NESDA analysis (147,478 + 2,905) higher CRP tracked the anxiety symptoms of irritability (OR 1.06) and worrying control (OR 1.03). But Mendelian randomization reverses the sign for CRP: genetically-predicted higher CRP concentration was associated with decreased risks of depressive and anxiety symptoms, while genetically-predicted higher IL-6 activity was associated with increased depressive symptom risk. The authors' own conclusion attributes the causal candidate to the IL-6/IL-6R pathway, not to CRP — CRP is a marker that rises with inflammation, not the agent. And they state the gap directly: MR studies of inflammation and anxiety ARE lacking, and the field now requires experimental studies of IL-6 modulation in humans to examine causality. Anything that lowers CRP has not thereby been shown to lower anxiety. doi 10.1038/s41380-021-01188-w · PMC8413248

Sleep reduces it.

The relationship is a loop, not an arrow, and the loop is the pathology: sleep disturbance activates inflammatory pathways and heightens stress reactivity, while persistent disturbance is associated with elevated CRP and IL-6; together these sustain a vicious cycle of hyperarousal and low-grade inflammation that transforms an adaptive short-term response into a chronic pathological process. Acute is not chronic, and the source is explicit: acute deprivation alone does not reliably raise these markers — one bad night is not the mechanism; persistence is. Mechanism at the cell level: chronic stress and sleep disruption bias microglia toward a pro-inflammatory state and alter astrocytic functions that gate sleep and metabolic clearance; chronic fragmentation also impairs glymphatic transport, which is enhanced during deep sleep. doi 10.1371/journal.pmen.0000531

Social bonding hormone reduces it.

Node the imaging is strong and replicated: the landmark finding is that oxytocin reduces amygdala responses to threatening face stimuli. In generalized social anxiety disorder the well-known left amygdala hyper-reactivity to fearful faces was reduced after intranasal oxytocin versus placebo, while improving the subjects' calmness score. A randomized placebo-controlled crossover trial found oxytocin attenuated right amygdala reactivity to fearful and angry faces (t(33)=3.32, pFWE=0.035). And the systematic review of randomized trials is null: across 15 RCTs in social anxiety disorder, arachnophobia, major depression and post-natal depression, results showed NO significant effects on core SYMPTOMATOLOGY, and the authors conclude the evidence for treating anxiety and depression is still inconclusive. The sign depends on WHO takes it — this edge is in the conditional table: raised amygdala reactivity in trauma-exposed healthy controls while reducing it in PTSD patients, attributed to lower endogenous oxytocin in the patients. And chronic dosing may undo it: oxytocin receptors show extensive internalization and desensitization after repeated administration, amygdala receptors may be particularly susceptible, and in rodents chronic administration can produce social impairment with reduced receptor expression in amygdala and nucleus accumbens — whereas every positive human trial above used a single dose. The reading: this pathway earns its place because it is real and widely sold, and the atlas should be the place a reader learns that the scan and the symptom do not agree. doi 10.1186/s40360-025-00996-y · PMID 30690935 · PMC12380973

The Two-Faced Peptide increases it.

10.1371/journal.pone.0008528 — The control is what makes this strong — it is anatomical, not just pharmacological: local injection of the kor antagonist norBNI into the basolateral amygdala blocked the stress- or crf-induced increase in anxiety-like behavior, whereas the same antagonist injected into a nearby thalamic nucleus did not. Same drug, millimeters apart, opposite result — the effect is located, not systemic. doi 10.1371/journal.pone.0008528

Training load reduces it.

anxiety is the most heavily swept outcome here: four independent enumerations, roughly twenty searches, twenty-one sibling relationships worked. It did not have one of the best-evidenced anxiolytic interventions in existence. The rule that found it uses no words: exercise drives mood and sleep, both of which share drivers with anxiety, so exercise was implied by the edge list alone. Twenty-seven randomized controlled trials, 1447 participants, in people diagnosed with an anxiety disorder or identified as high-anxiety on validated scales: exercise demonstrated a significant anxiolytic effect, Cohen d = -0.42, p < 0.01, using a three-level model that accounts for effect-size dependency. And the prescription is specified: optimal outcomes with programs under 12 weeks, sessions of 45-60 minutes, more than 3 times per week, and total weekly duration of at least 180 minutes. In youth (27 RCTs, 2022 participants) the overall effect was SMD -0.36, and adherence decided it: high adherence to the exercise prescription gave -0.67 while low or uncertain adherence gave -0.13 and was not significant (p = 0.21). Dose is the whole difference between a real effect and nothing. Publication bias is present and the authors found it themselves: visual inspection showed funnel plot asymmetry and a multilevel Egger regression detected small-study effects (estimate -2.29, SE 1.02, z = -2.25, p = 0.024) — smaller trials reported larger effects. The true effect is very likely below d = -0.42. And comorbidity blunts it: comorbid chronic conditions attenuated efficacy to d = -0.29. doi 10.1016/j.ctim.2026.103328 · PMC12846938

What it drives

It reduces Heart & blood pressure.

A search phrased in wellness terms returned four consumer health sites and two reviews about PTSD and chronic stress — no usable anxiety-specific evidence. That returned 46 cohort studies and 2,017,276 participants. The search terms were the problem, not the literature. The numbers: cardiovascular mortality RR 1.41 (1.13-1.76), coronary heart disease RR 1.41 (1.23-1.61), stroke RR 1.71 (1.18-2.50), across 222,253 people with anxiety. A second meta-analysis of 249,846 people over a mean 11.2 years gives CHD HR 1.26 and cardiac death HR 1.48, independent of demographic variables, biological risk factors, and health behaviors. And a null inside the same analysis, which is why the conditional exists: NONFATAL myocardial infarction HR 1.43, 95% CI 0.85 to 2.40, p = 0.180. The point estimate is as large as the significant ones and the interval crosses one. independent of depression, which is the non-obvious UK Biobank, 431,973 people — anxiety only HR 1.72, depression only 2.07, both 2.89, with very little evidence of multiplicative OR additive interaction. The authors recommend anxiety disorder should be considered for inclusion in CVD risk prediction and stratification. The authors’ own whether these associations ARE causal is unclear. All observational; thorough adjustment is not randomization. PMID 27324160 · PMC10377450

It increases Blood pressure.

A meta-analysis found A 40 percent excess risk of hypertension among those with anxiety disorder, and those with anxiety disorder are more likely to have cvd risk factors, such as hypertension and diabetes. This edge may therefore be partly carried by that route rather than being independent of it — stated rather than assumed away. Observational, and the excess-risk figure is quoted at second hand within a cohort study rather than read from the meta-analysis directly. PMC10377450

It reduces Memory & focus.

Meta-analysis of nine prospective cohorts, 29,608 participants: prevalent anxiety at baseline confers 24 percent higher risk of all-cause dementia. And the authors do the most useful thing a paper can do with a small effect - they size it against known risk factors: despite this being considered a low effect size, with an average of 20 percent of people with anxiety, the proportion of incident dementia attributable to anxiety is estimated to be 4 percent - comparable to diabetes at 3.2 percent and hypertension at 5.1 percent. A modest relative risk in a very common exposure outweighs a large relative risk in a rare one. And the conditional carries something this pathway uniquely has: two opposite interaction results. For cardiovascular disease, anxiety acts independently of depression - very little evidence of multiplicative OR additive interaction across 431,973 people. For type 2 diabetes, anxiety alone did nothing - risk appeared only in anxiety-insomnia comorbidity (HR 1.40) and not with each disorder separately. Same exposure, two companions, opposite structures. Anyone modeling anxiety as a uniform risk multiplier is wrong in one of those two directions. The authors call anxiety a potentially modifiable risk factor and note the results ARE still controversial. Observational throughout, and reverse causation is a live concern for dementia in particular, where prodromal anxiety may be an early symptom rather than a cause. doi 10.3390/jcm9061791 · PMC10377450

It reduces Sexual function.

Named across five reviews of erectile and female arousal physiology. Key contributors include reduced nitric oxide bioavailability due to endothelial oxidative stress and inflammation, diminished cavernosal smooth muscle content leading to impaired veno-occlusion, and increased arterial stiffness compounded by metabolic disorders. doi 10.21037/tau-2025-419 · PMID 19138376 · PMC11988752

It reduces Female libido.

It reduces Stress resilience.

Verbatim: “Our findings confirm the increased risk of animals with high anxiety developing certain depression-like behaviors (e.g., increased floating time in the forced swim test) when progressively exposed to stress”. doi 10.1016/j.psyneuen.2011.12.014 · PMID 22240307

It increases Calm pain signaling.

The defining feature is that the pain is real and the tissue is not damaged: central sensitization manifests as hyperalgesia, allodynia, expanded receptive fields, and impaired endogenous pain inhibition, and in osteoarthritis the same phenomenon does not correlate with radiographic findings - severe pain may persist despite stable joint structure. The mechanism is a balance failure in both directions at once: in the dorsal horn there is excessive release of glutamate, ATP, and substance P, leading to activation of NMDA receptors - while at the same time descending inhibitory mechanisms, notably those mediated by GABA, ARE weakened. Too much excitation and too little inhibition. And mast cells carry a specific hypothesis: thalamic mast cells releasing histamine, IL-1-beta, IL-6, TNF, CGRP and substance P, either stimulating thalamic nociceptive neurons directly or via microglia. Stated by the authors as a hypothesis, not an established mechanism. The reviewers ARE blunt about the state of knowledge: the pathophysiology and etiopathogenesis remain largely unknown, and there is NO definitive pathogenesis except for altered central pain pathways. doi 10.3390/biomedicines12071543 · PMC6687840

It increases Temperature stability in menopause.

10.2147/IJWH.S491640 — Drawn from reviews of neighboring outcomes rather than from studies of this outcome itself, which is weaker evidence, and the map marks it so. doi 10.2147/IJWH.S491640

It reduces Sleep.

sleep disturbance and anxiety form a vicious cycle — disturbance heightens stress reactivity, which further degrades sleep. doi 10.1038/s41380-021-01188-w · PMC8413248

It reduces Selective attention.

This meta-analysis of 172 studies (N = 2,263 anxious, N = 1,768 nonanxious) examined the boundary conditions of threat-related attentional biases in anxiety. Overall, the results show that the bias is reliably demonstrated with different experimental paradigms and under a variety of experimental conditions, but that it is only an effect size of d = 0.45. Verbatim from the source for this edge — Psychological Bulletin 2007;133(1):1-24 (Bar-Haim, Lamy, Pergamin, Bak, PMC-indexed replication set cited in Clin Psychol Rev S088761852200048.